ATE421512T1 - Inhibitoren von mitotischem kinesin - Google Patents

Inhibitoren von mitotischem kinesin

Info

Publication number
ATE421512T1
ATE421512T1 AT04780791T AT04780791T ATE421512T1 AT E421512 T1 ATE421512 T1 AT E421512T1 AT 04780791 T AT04780791 T AT 04780791T AT 04780791 T AT04780791 T AT 04780791T AT E421512 T1 ATE421512 T1 AT E421512T1
Authority
AT
Austria
Prior art keywords
inhibitors
mitotic kinesin
compounds
ksp kinesin
treating
Prior art date
Application number
AT04780791T
Other languages
English (en)
Inventor
Paul Coleman
Christopher Cox
Robert Garbaccio
George Hartman
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE421512T1 publication Critical patent/ATE421512T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04780791T 2003-08-15 2004-08-11 Inhibitoren von mitotischem kinesin ATE421512T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49563703P 2003-08-15 2003-08-15
US56358004P 2004-04-19 2004-04-19

Publications (1)

Publication Number Publication Date
ATE421512T1 true ATE421512T1 (de) 2009-02-15

Family

ID=34221386

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04780791T ATE421512T1 (de) 2003-08-15 2004-08-11 Inhibitoren von mitotischem kinesin

Country Status (15)

Country Link
US (2) US20060234984A1 (de)
EP (1) EP1664026B1 (de)
JP (1) JP4773961B2 (de)
AT (1) ATE421512T1 (de)
AU (1) AU2004266232B2 (de)
CA (1) CA2534065A1 (de)
CY (1) CY1108927T1 (de)
DE (1) DE602004019229D1 (de)
DK (1) DK1664026T3 (de)
ES (1) ES2319429T3 (de)
HR (1) HRP20090195T1 (de)
PL (1) PL1664026T3 (de)
PT (1) PT1664026E (de)
SI (1) SI1664026T1 (de)
WO (1) WO2005019206A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1515949B1 (de) 2002-06-14 2007-03-14 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
KR20050010515A (ko) * 2002-06-14 2005-01-27 머크 앤드 캄파니 인코포레이티드 유사분열 키네신 억제제
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
WO2004110998A1 (en) * 2003-05-16 2004-12-23 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
EP1656146A4 (de) 2003-08-15 2009-04-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
CN1835746A (zh) 2003-08-15 2006-09-20 默克公司 有丝分裂驱动蛋白抑制剂
EP1664026B1 (de) * 2003-08-15 2009-01-21 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
US20070225499A1 (en) * 2004-04-19 2007-09-27 Gary Javadi Process for the Preparation of 2,2-Disubstituted Pyrroles
WO2006007497A2 (en) 2004-07-01 2006-01-19 Merck & Co., Inc. Prodrugs of mitotic kinesin inhibitors
WO2006060737A2 (en) * 2004-12-03 2006-06-08 Takeda San Diego, Inc. Mitotic kinesin inhibitors
CN101137372A (zh) * 2005-03-16 2008-03-05 默克公司 有丝分裂驱动蛋白抑制剂
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
JP5455915B2 (ja) 2007-10-19 2014-03-26 メルク・シャープ・アンド・ドーム・コーポレーション Kspキネシン活性を阻害するためのスピロ縮合した1,3,4−チアジアゾール誘導体
JO3465B1 (ar) 2008-06-19 2020-07-05 Takeda Pharmaceuticals Co مركب متغاير الحلقه واستخدامه
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション p53活性を増大する置換ピペリジン及びその使用
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (de) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina)
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
EP3766975A1 (de) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
EP2654748B1 (de) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
AU2012220572A1 (en) * 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3358013B1 (de) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Sina-zusammensetzungen
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
DK2925888T3 (en) 2012-11-28 2017-12-18 Merck Sharp & Dohme COMPOSITIONS AND METHODS OF CANCER TREATMENT
EP2935263B1 (de) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Substituierte imidazopyridine als hdm2 inhibitoren
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CN104370939B (zh) * 2014-10-14 2016-10-26 上海交通大学 一种手性二氢吡咯类化合物的制备方法
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
WO2018190719A2 (en) 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833668B1 (de) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5-inhibitoren
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren
BR112021002267A8 (pt) 2018-08-07 2023-02-07 Merck Sharp & Dohme Inibidores de prmt5
BR112022012015A2 (pt) 2019-12-17 2022-08-30 Merck Sharp & Dohme Llc Inibidores de prmt5
EP4076459B1 (de) 2019-12-17 2026-04-29 Merck Sharp & Dohme LLC Prmt5-inhibitoren
CA3160153A1 (en) 2019-12-17 2021-06-24 Michelle Machacek Prmt5 inhibitors
EP4076460B1 (de) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidin]-derivate als prmt5 inhibitoren zur behandlung von krebs
EP4301744A1 (de) 2021-08-10 2024-01-10 AbbVie Inc. Nicotinamid-ripk1-inhibitoren
WO2026027944A1 (en) 2024-07-30 2026-02-05 Sairopa B.V. Anti-sirp alpha antibody formulations and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3142699A (en) * 1958-04-24 1964-07-28 Bayer Ag Urethane compounds and process therefor
US3647790A (en) * 1969-04-08 1972-03-07 American Home Prod Ouinoxalinyl-oxazolidines and -oxazines
US4477389A (en) * 1982-10-25 1984-10-16 The United States Of America As Represented By The Secretary Of Agriculture Polyhalogenated phenyl isocyanate synthesis with excess phosgene and either triethylamine or tetramethylurea
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
JP2000516234A (ja) 1996-08-16 2000-12-05 デュポン ファーマシューティカルズ カンパニー アミジノフェニル―ピロリジン類、アミジノフェニル―ピロリン類、およびアミジノフェニル―イソオキサゾリジン類およびそれらの誘導体
US6057342A (en) * 1996-08-16 2000-05-02 Dupont Pharmaceutical Co. Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
US6440686B1 (en) * 2000-06-15 2002-08-27 Cytokinetics, Inc. Methods for screening and therapeutic applications of kinesin modulators
AU2002363960B2 (en) 2001-12-06 2008-07-10 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
JP2003177052A (ja) * 2001-12-13 2003-06-27 Takata Corp シート重量計測装置
AU2003249597B2 (en) * 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
CA2485343A1 (en) * 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2003231799A1 (en) * 2002-05-23 2003-12-12 Merck & Co., Inc. Mitotic kinesin inhibitors
KR20050010515A (ko) * 2002-06-14 2005-01-27 머크 앤드 캄파니 인코포레이티드 유사분열 키네신 억제제
EP1515949B1 (de) * 2002-06-14 2007-03-14 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
US6835899B2 (en) * 2002-08-21 2004-12-28 Trw Inc. Load sensing assembly for a vehicle seat
AU2003287057B2 (en) * 2002-10-18 2008-08-21 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
WO2004111193A2 (en) * 2003-06-12 2004-12-23 Merck & Co., Inc. Prodrugs of mitotic kinesin inhibitors
ATE426605T1 (de) * 2003-06-12 2009-04-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
WO2005018638A1 (en) * 2003-08-13 2005-03-03 Merck & Co., Inc. Mitotic kinesin inhibitors
CN1835746A (zh) * 2003-08-15 2006-09-20 默克公司 有丝分裂驱动蛋白抑制剂
EP1664026B1 (de) * 2003-08-15 2009-01-21 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
PE20050730A1 (es) * 2003-08-15 2005-09-20 Merck & Co Inc Derivados de 2,5-dihidropirrol 2,2-disustituidos como inhibidores de quinesinas mitoticas
US7294640B2 (en) * 2004-02-06 2007-11-13 Merck & Co., Inc. Mitotic kinesin inhibitors

Also Published As

Publication number Publication date
CA2534065A1 (en) 2005-03-03
AU2004266232A1 (en) 2005-03-03
DK1664026T3 (da) 2009-05-04
US20050043357A1 (en) 2005-02-24
JP2007502774A (ja) 2007-02-15
EP1664026A1 (de) 2006-06-07
JP4773961B2 (ja) 2011-09-14
HRP20090195T1 (hr) 2009-05-31
PT1664026E (pt) 2009-04-23
US20060234984A1 (en) 2006-10-19
EP1664026B1 (de) 2009-01-21
ES2319429T3 (es) 2009-05-07
DE602004019229D1 (de) 2009-03-12
PL1664026T3 (pl) 2009-06-30
SI1664026T1 (sl) 2009-04-30
CY1108927T1 (el) 2014-07-02
WO2005019206A1 (en) 2005-03-03
AU2004266232B2 (en) 2008-07-03
US7465746B2 (en) 2008-12-16

Similar Documents

Publication Publication Date Title
DE602004019229D1 (de) Inhibitoren von mitotischem kinesin
ATE446094T1 (de) Mitotische kinesin-hemmer
ATE356804T1 (de) Inhibitoren von mitotischem kinesin
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
ATE448207T1 (de) Mitotische kinesin-hemmer
ATE424388T1 (de) Mitotische kinesinhemmer
ATE447577T1 (de) Mitotische kinesin-hemmer
WO2005017190A3 (en) Mitotic kinesin inhibitors
WO2004037171A3 (en) Mitotic kinesin inhibitors
WO2005018547A3 (en) Mitotic kinesin inhibitors
WO2004039774A3 (en) Mitotic kinesin inhibitors
WO2003099211A3 (en) Mitotic kinesin inhibitors
ECSP066362A (es) Inhibidores de quinesina mitótica.
WO2004058700A3 (en) Mitotic kinesin inhibitors
WO2004058148A3 (en) Mitotic kinesin inhibitors
WO2005060654A3 (en) Mitotic kinesin inhibitors
WO2005065183A3 (en) Mitotic kinesin inhibitors
NO20070589L (no) Mitotiske kinesin-inhibitorer.
ATE426605T1 (de) Inhibitoren von mitotischem kinesin
WO2006023440A3 (en) Mitotic kinesin inhibitors
WO2004087050A3 (en) Mitotic kinesin inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1664026

Country of ref document: EP

EEFA Change of the company name